Berkshire Hathaway has closed its $9.7 billion purchase of OxyChem from Occidental, integrating a leading North American manufacturer of polyvinyl chloride, chlor-alkali and chlorinated organic chemicals. The deal strengthens Berkshire’s industrial segment by adding a top-three U.S. provider of essential chemicals used in water treatment, pharmaceuticals, construction and manufacturing.

OxyChem’s operations span multiple production facilities across North America and produce calcium chloride along with specialty chemistries vital to automotive, healthcare and consumer markets. Management led by OxyChem CEO Wade Alleman will remain in place, ensuring continuity as Berkshire seeks to leverage its financial strength to expand capacity and drive synergies.

Greg Abel, Berkshire’s new chairman and CEO, sold 1.7 million shares of DaVita under a prearranged trading plan, marking his first divestiture of a long-held position. The sale was executed under a contractual agreement and does not alter Berkshire’s overall stake in DaVita, which remains a noncore investment within its equity portfolio.

Abel also filed to sell nearly all of Berkshire’s 325 million Kraft Heinz shares, signaling disapproval of the food company’s planned split and highlighting a shift away from legacy positions. The move could free capital for redeployment into more strategic holdings aligned with Berkshire’s long-term industrial growth strategy.